<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35713">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641639</url>
  </required_header>
  <id_info>
    <org_study_id>OX4325</org_study_id>
    <nct_id>NCT02641639</nct_id>
  </id_info>
  <brief_title>FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer</brief_title>
  <official_title>FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase
      2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC
      plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC).
      Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or
      fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC
      plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs.
      paclitaxel), platinum free interval (&lt; 3 vs. 3 to 6 months from last platinum therapy to
      subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study,
      consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study
      (Part 2). Both parts of the study will have similar overall design. Approximately 80
      subjects will be randomized into Part 1 and approximately 356 subjects will be randomized
      into Part 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase
      2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC
      plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC).
      Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or
      fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC
      plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs.
      paclitaxel), platinum free interval (&lt; 3 vs. 3 to 6 months from last platinum therapy to
      subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study,
      consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study
      (Part 2). Both parts of the study will have similar overall design. Approximately 80
      subjects will be randomized into Part 1 and approximately 356 subjects will be randomized
      into Part 2.

      All subjects randomized will receive bevacizumab 10 mg/kg intravenously (IV) on Days 1 and
      15, repeated every 4 weeks (q4wk) and PCC with paclitaxel 80 mg/m2 IV on Days 1, 8, 15 and
      22, repeated q4wk, or paclitaxel 80 mg/m2 IV on Days 1, 8, 15, repeated q4wk or PLD 40 mg/m2
      IV on Day 1, repeated q4wk. Subjects in the Treatment Arm will also receive CA4P 60 mg/m2 on
      the same day as bevacizumab (Days 1 and 15, repeated q4wk), while subjects in the Control
      Arm will receive placebo on those days.

      Order of dosing will follow the guidance listed below during this study when bevacizumab and
      CA4P / Placebo are dosed the same day as PCC,

        -  Bevacizumab followed by CA4P / Placebo followed after 1-3 hours by paclitaxel,

        -  PLD followed by bevacizumab followed by CA4P / Placebo Subjects will continue
           randomized treatment until disease progression, unacceptable toxicity, investigator
           decision, withdrawal of consent, or sponsor discontinues study for any reason. Subjects
           will undergo tumor assessments (RECIST) at baseline and every 8 weeks and CA-125 levels
           at baseline and every 4 weeks.

      The primary endpoint is PFS. Secondary endpoints include ORR, OS, proportion of subjects who
      remain progression free at 6, 9, and 12 months, and safety. Endpoints will be compared
      between the Treatment Arm and the Control arm. The study duration is estimated to last
      approximately 3 years.

      This study will have 2 parts with the same overall design. Part 1 will enroll up to
      approximately 80 subjects and will include multiple interim analyses to test the safety and
      efficacy assumptions in this specific subject population. Upon meeting certain efficacy
      criteria in Part 1, the protocol will be amended and additional sites added in order to
      enroll an additional 356 subjects into Part 2 of the study. Subjects enrolled in Part 2 will
      be analyzed separately and used as a stand-alone confirmatory efficacy study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Minimum 12 months</time_frame>
    <description>The primary efficacy parameter in this study is statistically meaningful PFS, defined as the time from the date of randomization until patient discontinuation or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in objective response rate</measure>
    <time_frame>Minimum 12 Months</time_frame>
    <description>Improvement in objective response rate (ORR), using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG) cancer antigen-125 (CA-125) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall survival (OS)</measure>
    <time_frame>Minimum 12 Months</time_frame>
    <description>Evaluation of overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who remain progression-free at 6, 9, and 12 months</measure>
    <time_frame>Minimum 12 Months</time_frame>
    <description>Assessment of the proportion of subjects who remain progression-free at 6, 9, and 12 months on the regimen of PCC plus bevacizumab and CA4P compared with PCC plus bevacizumab and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo</measure>
    <time_frame>Minimum 12 Months</time_frame>
    <description>To evaluate the Incidence of Treatment-Emergent Adverse Events of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo as measured by aggregate reporting of the number of patient with abnormal findings on (physical exams, vital signs, laboratory measures, ECG, Eastern Cooperative Oncology Group (ECOG) performance status (PS)) and/or analysis of the incidence of adverse events (AEs) using the National Cancer Institute (NCI)-Common Terminology Criteria for AEs (CTCAE) version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">436</enrollment>
  <condition>Platinum Resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Fosbretabulin tromethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosbretabulin tromethamine</intervention_name>
    <description>CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.</description>
    <arm_group_label>Fosbretabulin tromethamine</arm_group_label>
    <other_name>Fosbretabulin Combretastatin A4-Phosphate, CA4P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline for infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline for infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form (ICF)

          2. Age ≥ 18 years (Age ≥ 19 years if required by local regulatory authorities)

          3. ECOG PS of 0-1

          4. Histologically or cytologically-confirmed epithelial ovarian, fallopian tube or
             primary peritoneal cancer in recurrent stage

          5. prOC (platinum-resistant ovarian cancers) defined as progression within &gt;1 to &lt;6
             months of receiving last platinum-based therapy

          6. Received ≥ 1 but ≤ 2 prior platinum-based regimens

          7. Measurable disease according to RECIST 1.1

          8. Left ventricular ejection fraction (LVEF) greater than or equal to at least 45% at
             baseline assessment if subject is receiving PLD, and/or anthracycline is a
             concomitant medication

          9. No evidence of active (progressing) brain metastasis. (Treated brain metastasis
             allowed with a posttreatment magnetic resonance imaging (MRI) or Computed Tomography
             (CT) of brain showing no active (progressing) brain metastasis). Treatment of brain
             metastasis may include surgery, radiosurgery (linear accelerator (LINAC), gamma
             knife), or whole brain irradiation. Surgery for brain metastasis must be &gt; 8 weeks
             from study entry

         10. Hemoglobin &gt; 9 g/dL without transfusions or growth factors

         11. Adequate bone marrow function in the investigator's opinion

         12. Adequate hepatic function defined by the following:

               -  Total bilirubin &lt; 2 x Upper Limit of Normal (ULN)

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 X ULN
                  for the referenced lab (&lt; 5 X ULN for subjects with liver metastases)

         13. Adequate renal function defined by the following:

             − Serum creatinine &lt; 2 X ULN for the referenced lab

         14. Subjects of childbearing potential must have a negative serum pregnancy test prior to
             study entry and must be practicing a highly effective form of contraception

         15. At least 2 weeks since prior radiotherapy and has recovered from any Grade 3
             toxicities

         16. Life expectancy ≥ 12 weeks

        Exclusion Criteria:

          1. Subjects who have received prior CA4P therapy

          2. Previously having failed treatment with bevacizumab combined with the intended PCC.

             − For clarity: Investigators should not select a bevacizumab + PCC combination for
             the FOCUS trial if the patient has previously failed that same regimen, however they
             may select a new PCC regimen to combine with bevacizumab. For example, a patient who
             failed bevacizumab + weekly paclitaxel would be allowed to enroll in FOCUS only if
             they are assigned to bevacizumab + PLD for the study.

          3. Previous treatment with greater than two chemotherapy treatment regimens

          4. Untreated brain metastasis or leptomeningeal brain metastasis

          5. Solid organ or bone marrow transplant

          6. Primary platinum-refractory disease (defined as progression during or within one (1)
             month of completing patients first platinum-containing regimen)

          7. &gt; Grade 2 peripheral neuropathy

          8. Current thrombotic or hemorrhagic disorder/event or history of prior event within 6
             months of start of Screening

          9. History of prior cerebrovascular event, (including transient ischemic attack) within
             6 months of start of Screening

         10. Recent history (within 6 months of start of Screening) of angina pectoris, myocardial
             infarction (including non-Q wave MI), or NYHA Class III and IV congestive heart
             failure

         11. History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic
             sinus bradycardia (&lt;60 bpm), heart block (excluding 1st degree block, benign PR
             interval prolongation only), congenital long QT syndrome or new ST segment elevation
             or depression or new Q wave on ECG

         12. Known uncontrolled HIV infection

         13. Uncontrolled, clinically significant active infection

         14. Serious non-healing wound, ulcer or bone fracture

         15. Subjects with known hypersensitivity to any of the components of CA4P, paclitaxel,
             PLD, or bevacizumab (paclitaxel and PLD dependent on whether PI plans they will be
             dosed with that PCC)

         16. Subjects who are currently or planning on receiving concurrent investigational
             therapy or who have received investigational therapy for any indication within 30
             days of the first scheduled day of dosing

         17. Subjects with any other intercurrent medical condition, including mental illness or
             substance abuse, deemed by the Investigator to be likely to interfere with a
             subject's ability to provide informed consent, cooperate and participate in the
             study, or to interfere with the interpretation of the study results

         18. Subjects with other invasive malignancies, with the exception of non-melanoma skin
             cancer, or with previous cancer treatment that contraindicates this protocol therapy
             within last 5 years

         19. Prior radiation therapy to the pelvis or abdomen within 4 weeks of entry into the
             study

         20. History of fistula, gastrointestinal (GI) perforation or intra-abdominal abscess, or
             invasive disease/metastases of the bowel which may increase the risk of GI
             perforation with bevacizumab treatment.

         21. Uncontrolled hypertension (HTN)

             − Sustained BP greater than 150 mmHG SBP / 100 mmHG DBP

         22. Uncontrolled elevated proteinuria levels in the investigator's opinion

         23. Corrected QT interval ([QTc] Fridericia) &gt; 480 ms

         24. Significant vascular disease or recent peripheral arterial thrombosis

         25. Subjects with active bleeding or pathologic conditions that carry high risk of
             bleeding

         26. Subjects who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gelder, MD</last_name>
    <role>Study Director</role>
    <affiliation>Backup Medical Monitor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harish Dave, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Cram, BS</last_name>
    <phone>650-635-7018</phone>
    <email>ccram@mateon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Couchenour, PharmD, MBA</last_name>
    <phone>650-635-7045</phone>
    <email>RCouchenour@Mateon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Burton, RN, BSN</last_name>
      <phone>205-934-6454</phone>
      <email>asb2013@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Charles A Leath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea McNeil</last_name>
      <phone>602-277-4868</phone>
      <email>andrea.mcneil@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Snehalkumar M Bhoola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimble</last_name>
      <phone>520-886-0206</phone>
      <email>stacey.kimball@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bookman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <zip>90262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Michael Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Wallick</last_name>
      <phone>714-456-6191</phone>
      <email>awallick@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Randall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center, Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isheen Herrara</last_name>
      <phone>415-600-3619</phone>
      <email>herreri@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>John Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-563-5800</phone>
      <email>hheitkam@ccsb.com</email>
    </contact>
    <investigator>
      <last_name>Julie Taguchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-285-5081</phone>
      <email>valerie.apodaca@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ling Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital - Bennett Cancer Center</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megha Shah, LPN</last_name>
      <phone>203-276-8453</phone>
      <email>mshah@stamhealth.org</email>
    </contact>
    <investigator>
      <last_name>Salvatore A. Del Prete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <email>m.mikhail@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Brian M Slomovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetsenea Coto</last_name>
      <phone>786-527-8111</phone>
      <email>JetseneaC@baptisthealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Suarez</last_name>
      <phone>305-595-2141</phone>
      <email>deborahtcv@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>John Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Dorman</last_name>
      <phone>813-745-7272</phone>
      <email>denise.dorman@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Robert Wenham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Wheatley, LPN</last_name>
      <phone>706-721-8978</phone>
      <email>dwheatley@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad A Ghamande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Allen</last_name>
      <phone>207-396-7069</phone>
      <email>ALLEND2@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Darus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Division - Sarah Cannon Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Stawinski, MBA</last_name>
      <phone>816-276-9786</phone>
      <email>sharon.stawinski@HCAMidwest.com</email>
    </contact>
    <investigator>
      <last_name>Shawn K LyBarger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heath Sciences Center - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Cleaver</last_name>
      <phone>405-271-8777</phone>
      <email>Nancy-Cleaver@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell, RN, BSN, OCN</last_name>
      <phone>918-505-3201</phone>
      <phone_ext>4075</phone_ext>
      <email>Melissa.Powell@OCSRI.ORG</email>
    </contact>
    <investigator>
      <last_name>Michael Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bauldauf, MEd</last_name>
      <phone>412-578-4517</phone>
      <email>ebaldauf@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Krivak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center &amp; Research Institute Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Weathers</last_name>
      <phone>864-560-1039</phone>
      <email>dweathers@gibbscc.org</email>
    </contact>
    <contact_backup>
      <last_name>Vickie Kloth, BS</last_name>
      <phone>864.560.1034</phone>
      <email>vkloth@gibbscc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaelyn Kappeler</last_name>
      <phone>512-421-4100</phone>
      <email>kaelyn.kappeler@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Clark</last_name>
      <phone>214-370-1000</phone>
      <email>Kelly.clark@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Monique Spillman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Fitzgerald</last_name>
      <phone>281-296-0365</phone>
      <email>anne.fitzgerald@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine M Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-579-9800</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joke De Roover</last_name>
      <phone>+32 16 34 74 19</phone>
      <email>joke.deroover@uz.kuleuven.ac.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 11, 2017</lastchanged_date>
  <firstreceived_date>December 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
    <mesh_term>Fosbretabulin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
